The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

SAMSN1  -  SAM domain, SH3 domain and nuclear...

Homo sapiens

Synonyms: HACS1, Hematopoietic adaptor containing SH3 and SAM domains 1, NASH1, Nash1, SAM domain, SH3 domain and nuclear localization signals protein 1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of SAMSN1


Psychiatry related information on SAMSN1

  • This notion, now called the "Nash equilibrium," has been widely applied and adapted in economics and other behavioral sciences [6].
  • Immunoreactivity was diffuse in cases of ALD, NASH and steatosis, and in patients with drug abuse [7].
  • Hibbard, Hilsenroth, Hibbard, and Nash (1995) found that affective, but not cognitive, dimensions of object representations were related to the severity of psychopathology among outpatients [8].
  • Validity of the measures was supported by significant correlations with scores on the Physical subscale of the Tennessee Self-Concept Scale (r = .60 to .63) as well as by significant differences on the three measures between normal-weight and overweight groups (Nash: F = 28.03, p = .001; Photo: F = 11.58, p = .001) [9].
  • Body image was found to be stable over the 1-year period on the Nash Body Image Scale and the Body Image Photo Technique [9].

High impact information on SAMSN1

  • Immunoblot analysis demonstrated that HACS1 is up-regulated by IL-4, IL-13, anti-IgM, and anti-CD40 in human peripheral blood B cells [1].
  • Our study demonstrates that HACS1 is up-regulated by B cell activation signals and is a participant in B cell activation and differentiation [1].
  • Pioglitazone Trial for NASH: Results Show Promise [10].
  • Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue [11].
  • We have previously shown (Nash, S., J. Stafford, and J.L. Madara. 1987. J. Clin. Invest. 80:1104-1113), that leukocyte migration across T84 monolayers, a model human intestinal epithelium, results in enhanced tight junction permeability--an effect quantitated by the use of a simple, standard electrical assay of transepithelial resistance [12].

Chemical compound and disease context of SAMSN1


Biological context of SAMSN1


Anatomical context of SAMSN1

  • In murine spleen B cells, Hacs1 can also be up-regulated by lipopolysaccharide but not IL-13 [1].
  • Polyclonal antibodies against HACS1 recognized a 49.5 kDa protein whose mRNA is expressed in human immune tissues, bone marrow, heart, lung, placenta and brain [2].
  • It was previously shown that band 3 in ovalocytic membranes has decreased rotational mobility compared with band 3 in normal cells (Tilley, L., Nash, G.B., Jones, G.L. and Sawyer, W.L. (1991) J. Membr. Biol. 121, 59-66) [21].
  • However, keratin IFs were soon identified as major cellular structures to be affected in a variety of chronic liver diseases, such as alcoholic and non-alcoholic steatohepatitis (ASH, NASH), copper toxicosis, and cholestasis [22].
  • In NASH, the localization of the adducts was in the cytoplasm of sinusoidal cells and hepatocytes with a predominance in zone 3 [23].

Associations of SAMSN1 with chemical compounds

  • Vitamin E therapy in patients with NASH [24].
  • The resulting enzymatically mediated production of formaldehyde was determined colorimetrically by the Nash reaction [25].
  • Orlistat in the treatment of NASH: a case series [26].
  • In this paper 828 servicemen killed and injured by explosions in Northern Ireland have been studied, using data stored in the Hostile Action Casualty System (HACS) [27].
  • Enlarged hepatocytes in NAFLD examined with osmium fixation: does microsteatosis underlie cellular ballooning in NASH [28]?

Regulatory relationships of SAMSN1


Analytical, diagnostic and therapeutic context of SAMSN1

  • Our results reveal possible strategies to bring Nash and utilitarian vaccination levels into alignment [29].
  • NAFLD and NASH: important diseases before and after liver transplantation [30].
  • Percutaneous rotational contact biliary lithotripsy: initial clinical results with the Kensey Nash lithotrite [31].
  • UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease [32].
  • Materials and methods In this cross-sectional case-control study, 48 cancer-free patients with non-alcoholic steatohepatitis (NASH, Group 1), 48 patients with pure fatty liver (FL, Group 2), and 47 volunteers (Group 3) were studied [33].


  1. The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades. Zhu, Y.X., Benn, S., Li, Z.H., Wei, E., Masih-Khan, E., Trieu, Y., Bali, M., McGlade, C.J., Claudio, J.O., Stewart, A.K. J. Exp. Med. (2004) [Pubmed]
  2. HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells. Claudio, J.O., Zhu, Y.X., Benn, S.J., Shukla, A.H., McGlade, C.J., Falcioni, N., Stewart, A.K. Oncogene (2001) [Pubmed]
  3. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., Poynard, T. Gastroenterology (2005) [Pubmed]
  4. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Marchesini, G., Forlani, G. Hepatology (2002) [Pubmed]
  5. Reduced plasma adiponectin in NASH: central obesity as an underestimated causative risk factor. Tietge, U.J., Schmidt, H.H., Schütz, T., Dippe, P., Lochs, H., Pirlich, M. Hepatology (2005) [Pubmed]
  6. The Nash equilibrium: a perspective. Holt, C.A., Roth, A.E. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  7. Identification of mitochondria in liver biopsies. A study by immunohistochemistry, immunogold and Western blot analysis. Foschini, M.P., Macchia, S., Losi, L., Dei Tos, A.P., Pasquinelli, G., Di Tommaso, L., Del Duca, S., Roncaroli, F., Dal Monte, P.R. Virchows Arch. (1998) [Pubmed]
  8. Cognitive and affective representations of people and MCMI-II personality psychopathology. Porcerelli, J.H., Cogan, R., Hibbard, S. Journal of personality assessment. (1998) [Pubmed]
  9. Body image measurement in overweight females. Popkess-Vawter, S., Banks, N. Clinical nursing research. (1992) [Pubmed]
  10. Pioglitazone Trial for NASH: Results Show Promise. Lang, L. Gastroenterology (2007) [Pubmed]
  11. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Angulo, P., Lindor, K.D. Gastroenterology (2001) [Pubmed]
  12. Neutrophil migration across a cultured epithelial monolayer elicits a biphasic resistance response representing sequential effects on transcellular and paracellular pathways. Parkos, C.A., Colgan, S.P., Delp, C., Arnaout, M.A., Madara, J.L. J. Cell Biol. (1992) [Pubmed]
  13. Comment on "Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients" by Nash and Zaltzman. Wirnsberger, G.H., Pfragner, R. Transplantation (1999) [Pubmed]
  14. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Liew, P.L., Lee, W.J., Lee, Y.C., Wang, H.H., Wang, W., Lin, Y.C. Obesity surgery : the official journal of the American Society for Bariatric Surgery and of the Obesity Surgery Society of Australia and New Zealand (2006) [Pubmed]
  15. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Loria, P., Lonardo, A., Leonardi, F., Fontana, C., Carulli, L., Verrone, A.M., Borsatti, A., Bertolotti, M., Cassani, F., Bagni, A., Muratori, P., Ganazzi, D., Bianchi, F.B., Carulli, N. Dig. Dis. Sci. (2003) [Pubmed]
  16. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Itoh, S., Kanazuka, A., Akimoto, T. Dig. Dis. Sci. (2003) [Pubmed]
  17. Lipid metabolism in hepatic steatosis. Bradbury, M.W., Berk, P.D. Clinics in liver disease. (2004) [Pubmed]
  18. Surface antigen variability and variation in Giardia lamblia. Nash, T. Parasitol. Today (Regul. Ed.) (1992) [Pubmed]
  19. Increased risk of NASH in patients carrying the C(-159)T polymorphism in the CD14 gene promoter region. Brun, P., Castagliuolo, I., Floreani, A.R., Buda, A., Blasone, L., Palù, G., Martines, D. Gut (2006) [Pubmed]
  20. Identification of a gene-pathway associated with non-alcoholic steatohepatitis. Rubio, A., Guruceaga, E., Vázquez-Chantada, M., Sandoval, J., Martínez-Cruz, L.A., Segura, V., Sevilla, J.L., Podhorski, A., Corrales, F.J., Torres, L., Rodríguez, M., Aillet, F., Ariz, U., Arrieta, F.M., Caballería, J., Martín-Duce, A., Lu, S.C., Martínez-Chantar, M.L., Mato, J.M. J. Hepatol. (2007) [Pubmed]
  21. Aggregation of band 3 in hereditary ovalocytic red blood cell membranes. Electron microscopy and protein rotational diffusion studies. Che, A., Cherry, R.J., Bannister, L.H., Dluzewski, A.R. J. Cell. Sci. (1993) [Pubmed]
  22. The keratin cytoskeleton in liver diseases. Zatloukal, K., Stumptner, C., Fuchsbichler, A., Fickert, P., Lackner, C., Trauner, M., Denk, H. J. Pathol. (2004) [Pubmed]
  23. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. Seki, S., Kitada, T., Yamada, T., Sakaguchi, H., Nakatani, K., Wakasa, K. J. Hepatol. (2002) [Pubmed]
  24. Vitamin E therapy in patients with NASH. Yoneda, M., Hasegawa, T., Nakamura, K., Tamano, M., Kono, T., Terano, A. Hepatology (2004) [Pubmed]
  25. Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). Bruhn, C., Brockmöller, J., Kerb, R., Roots, I., Borchert, H.H. Biochem. Pharmacol. (1998) [Pubmed]
  26. Orlistat in the treatment of NASH: a case series. Harrison, S.A., Ramrakhiani, S., Brunt, E.M., Anbari, M.A., Cortese, C., Bacon, B.R. Am. J. Gastroenterol. (2003) [Pubmed]
  27. Analysis of 828 servicemen killed or injured by explosion in Northern Ireland 1970-84: the Hostile Action Casualty System. Mellor, S.G., Cooper, G.J. The British journal of surgery. (1989) [Pubmed]
  28. Enlarged hepatocytes in NAFLD examined with osmium fixation: does microsteatosis underlie cellular ballooning in NASH? Caldwell, S.H., Redick, J.A., Chang, C.Y., Davis, C.A., Argo, C.K., Al Osaimi, K.A. Am. J. Gastroenterol. (2006) [Pubmed]
  29. Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Galvani, A.P., Reluga, T.C., Chapman, G.B. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  30. NAFLD and NASH: important diseases before and after liver transplantation. Yu, A.S., Keeffe, E.B. Hepatology (2001) [Pubmed]
  31. Percutaneous rotational contact biliary lithotripsy: initial clinical results with the Kensey Nash lithotrite. Miller, F.J., Rose, S.C., Buchi, K.N., Hunter, J.G., Nash, J.E., Kensey, K.R. Radiology. (1991) [Pubmed]
  32. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. Lazaridis, K.N., Gores, G.J., Lindor, K.D. J. Hepatol. (2001) [Pubmed]
  33. Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. Tarantino, G., Conca, P., Coppola, A., Vecchione, R., Di Minno, G. Eur. J. Clin. Invest. (2007) [Pubmed]
WikiGenes - Universities